Murine oncostatin m acts via leukemia inhibitory factor receptor to phosphorylate signal transducer and activator of transcription 3 (STAT3) but not STAT1, an effect that protects bone mass

Emma C Walker, Rachelle W Johnson, Yifang Hu, Holly J. Brennan, Ingrid J Poulton, Jian Guo Zhang, Brendan J. Jenkins, Gordon K Smyth, Nicos A Nicola, Natalie A. Sims

Research output: Contribution to journalArticleResearchpeer-review

13 Citations (Scopus)

Abstract

Oncostatin M (OSM) and leukemia inhibitory factor (LIF) are IL-6 family members with a wide range of biological functions. Human OSM (hOSM) and murine LIF (mLIF) act in mouse cells via a LIF receptor (LIFR)-glycoprotein 130 (gp130) heterodimer. In contrast, murine OSM (mOSM) signals mainly via an OSM receptor (OSMR)-gp130 heterodimer and binds with only very low affinity to mLIFR. hOSM and mLIF stimulate bone remodeling by both reducing osteocytic sclerostin and up-regulating the pro-osteoclastic factor receptor activator of NF-βB ligand (RANKL) in osteoblasts. In the absence of OSMR, mOSM still strongly suppressed sclerostin and stimulated bone formation but did not induce RANKL, suggesting that intracellular signaling activated by the low affinity interaction of mOSM with mLIFR is different from the downstream effects when mLIF or hOSM interacts with the same receptor. Both STAT1 and STAT3 were activated by mOSM in wild type cells or by mLIF/ hOSM in wild type and Osmr -/- cells. In contrast, in Osmr -/-primary osteocyte-like cells stimulated with mOSM (therefore acting through mLIFR), microarray expression profiling and Western blotting analysis identified preferential phosphorylation of STAT3 and induction of its target genes but not of STAT1 and its target genes; this correlated with reduced phosphorylation of both gp130 and LIFR. In a mouse model of spontaneous osteopenia caused by hyperactivation of STAT1/3 signaling downstream of gp130 (gp130Y757F/Y757F ), STAT1 deletion rescued the osteopenic phenotype, indicating a beneficial effect of promoting STAT3 signaling over STAT1 downstream of gp130 in this low bone mass condition, and this may have therapeutic value.

Original languageEnglish
Pages (from-to)21703-21716
Number of pages14
JournalJournal of Biological Chemistry
Volume291
Issue number41
DOIs
Publication statusPublished - 7 Oct 2016

Cite this

Walker, Emma C ; Johnson, Rachelle W ; Hu, Yifang ; Brennan, Holly J. ; Poulton, Ingrid J ; Zhang, Jian Guo ; Jenkins, Brendan J. ; Smyth, Gordon K ; Nicola, Nicos A ; Sims, Natalie A. / Murine oncostatin m acts via leukemia inhibitory factor receptor to phosphorylate signal transducer and activator of transcription 3 (STAT3) but not STAT1, an effect that protects bone mass. In: Journal of Biological Chemistry. 2016 ; Vol. 291, No. 41. pp. 21703-21716.
@article{3c866ab8c7604d309dc7bab1b3730f1d,
title = "Murine oncostatin m acts via leukemia inhibitory factor receptor to phosphorylate signal transducer and activator of transcription 3 (STAT3) but not STAT1, an effect that protects bone mass",
abstract = "Oncostatin M (OSM) and leukemia inhibitory factor (LIF) are IL-6 family members with a wide range of biological functions. Human OSM (hOSM) and murine LIF (mLIF) act in mouse cells via a LIF receptor (LIFR)-glycoprotein 130 (gp130) heterodimer. In contrast, murine OSM (mOSM) signals mainly via an OSM receptor (OSMR)-gp130 heterodimer and binds with only very low affinity to mLIFR. hOSM and mLIF stimulate bone remodeling by both reducing osteocytic sclerostin and up-regulating the pro-osteoclastic factor receptor activator of NF-βB ligand (RANKL) in osteoblasts. In the absence of OSMR, mOSM still strongly suppressed sclerostin and stimulated bone formation but did not induce RANKL, suggesting that intracellular signaling activated by the low affinity interaction of mOSM with mLIFR is different from the downstream effects when mLIF or hOSM interacts with the same receptor. Both STAT1 and STAT3 were activated by mOSM in wild type cells or by mLIF/ hOSM in wild type and Osmr -/- cells. In contrast, in Osmr -/-primary osteocyte-like cells stimulated with mOSM (therefore acting through mLIFR), microarray expression profiling and Western blotting analysis identified preferential phosphorylation of STAT3 and induction of its target genes but not of STAT1 and its target genes; this correlated with reduced phosphorylation of both gp130 and LIFR. In a mouse model of spontaneous osteopenia caused by hyperactivation of STAT1/3 signaling downstream of gp130 (gp130Y757F/Y757F ), STAT1 deletion rescued the osteopenic phenotype, indicating a beneficial effect of promoting STAT3 signaling over STAT1 downstream of gp130 in this low bone mass condition, and this may have therapeutic value.",
author = "Walker, {Emma C} and Johnson, {Rachelle W} and Yifang Hu and Brennan, {Holly J.} and Poulton, {Ingrid J} and Zhang, {Jian Guo} and Jenkins, {Brendan J.} and Smyth, {Gordon K} and Nicola, {Nicos A} and Sims, {Natalie A.}",
year = "2016",
month = "10",
day = "7",
doi = "10.1074/jbc.M116.748483",
language = "English",
volume = "291",
pages = "21703--21716",
journal = "Journal of Biological Chemistry",
issn = "1083-351X",
publisher = "American Society for Biochemistry and Molecular Biology",
number = "41",

}

Murine oncostatin m acts via leukemia inhibitory factor receptor to phosphorylate signal transducer and activator of transcription 3 (STAT3) but not STAT1, an effect that protects bone mass. / Walker, Emma C; Johnson, Rachelle W; Hu, Yifang; Brennan, Holly J.; Poulton, Ingrid J; Zhang, Jian Guo; Jenkins, Brendan J.; Smyth, Gordon K; Nicola, Nicos A; Sims, Natalie A.

In: Journal of Biological Chemistry, Vol. 291, No. 41, 07.10.2016, p. 21703-21716.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Murine oncostatin m acts via leukemia inhibitory factor receptor to phosphorylate signal transducer and activator of transcription 3 (STAT3) but not STAT1, an effect that protects bone mass

AU - Walker, Emma C

AU - Johnson, Rachelle W

AU - Hu, Yifang

AU - Brennan, Holly J.

AU - Poulton, Ingrid J

AU - Zhang, Jian Guo

AU - Jenkins, Brendan J.

AU - Smyth, Gordon K

AU - Nicola, Nicos A

AU - Sims, Natalie A.

PY - 2016/10/7

Y1 - 2016/10/7

N2 - Oncostatin M (OSM) and leukemia inhibitory factor (LIF) are IL-6 family members with a wide range of biological functions. Human OSM (hOSM) and murine LIF (mLIF) act in mouse cells via a LIF receptor (LIFR)-glycoprotein 130 (gp130) heterodimer. In contrast, murine OSM (mOSM) signals mainly via an OSM receptor (OSMR)-gp130 heterodimer and binds with only very low affinity to mLIFR. hOSM and mLIF stimulate bone remodeling by both reducing osteocytic sclerostin and up-regulating the pro-osteoclastic factor receptor activator of NF-βB ligand (RANKL) in osteoblasts. In the absence of OSMR, mOSM still strongly suppressed sclerostin and stimulated bone formation but did not induce RANKL, suggesting that intracellular signaling activated by the low affinity interaction of mOSM with mLIFR is different from the downstream effects when mLIF or hOSM interacts with the same receptor. Both STAT1 and STAT3 were activated by mOSM in wild type cells or by mLIF/ hOSM in wild type and Osmr -/- cells. In contrast, in Osmr -/-primary osteocyte-like cells stimulated with mOSM (therefore acting through mLIFR), microarray expression profiling and Western blotting analysis identified preferential phosphorylation of STAT3 and induction of its target genes but not of STAT1 and its target genes; this correlated with reduced phosphorylation of both gp130 and LIFR. In a mouse model of spontaneous osteopenia caused by hyperactivation of STAT1/3 signaling downstream of gp130 (gp130Y757F/Y757F ), STAT1 deletion rescued the osteopenic phenotype, indicating a beneficial effect of promoting STAT3 signaling over STAT1 downstream of gp130 in this low bone mass condition, and this may have therapeutic value.

AB - Oncostatin M (OSM) and leukemia inhibitory factor (LIF) are IL-6 family members with a wide range of biological functions. Human OSM (hOSM) and murine LIF (mLIF) act in mouse cells via a LIF receptor (LIFR)-glycoprotein 130 (gp130) heterodimer. In contrast, murine OSM (mOSM) signals mainly via an OSM receptor (OSMR)-gp130 heterodimer and binds with only very low affinity to mLIFR. hOSM and mLIF stimulate bone remodeling by both reducing osteocytic sclerostin and up-regulating the pro-osteoclastic factor receptor activator of NF-βB ligand (RANKL) in osteoblasts. In the absence of OSMR, mOSM still strongly suppressed sclerostin and stimulated bone formation but did not induce RANKL, suggesting that intracellular signaling activated by the low affinity interaction of mOSM with mLIFR is different from the downstream effects when mLIF or hOSM interacts with the same receptor. Both STAT1 and STAT3 were activated by mOSM in wild type cells or by mLIF/ hOSM in wild type and Osmr -/- cells. In contrast, in Osmr -/-primary osteocyte-like cells stimulated with mOSM (therefore acting through mLIFR), microarray expression profiling and Western blotting analysis identified preferential phosphorylation of STAT3 and induction of its target genes but not of STAT1 and its target genes; this correlated with reduced phosphorylation of both gp130 and LIFR. In a mouse model of spontaneous osteopenia caused by hyperactivation of STAT1/3 signaling downstream of gp130 (gp130Y757F/Y757F ), STAT1 deletion rescued the osteopenic phenotype, indicating a beneficial effect of promoting STAT3 signaling over STAT1 downstream of gp130 in this low bone mass condition, and this may have therapeutic value.

UR - http://www.scopus.com/inward/record.url?scp=84990940952&partnerID=8YFLogxK

U2 - 10.1074/jbc.M116.748483

DO - 10.1074/jbc.M116.748483

M3 - Article

VL - 291

SP - 21703

EP - 21716

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 1083-351X

IS - 41

ER -